Innocan Pharma Corp
XMUN:IP4
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Innocan Pharma Corp
XMUN:IP4
|
IL |
|
Borregaard ASA
F:BO4
|
NO |
|
Villars Holding SA
SIX:VILN
|
CH |
|
UOL Group Ltd
F:U1O
|
SG |
|
S
|
Sahakol Equipment PCL
SET:SQ
|
TH |
|
Turk Hava Yollari AO
IST:THYAO.E
|
TR |
|
Tenaris SA
NYSE:TS
|
LU |
|
A
|
Air Products and Chemicals Inc
DUS:AP3
|
US |
|
K
|
Kuaishou Technology
OTC:KSHTY
|
CN |
|
C
|
Canadian Natural Resources Ltd
XMUN:CRC
|
CA |
|
K
|
Kuehne und Nagel International AG
XMUN:KNIA
|
CH |
|
Impala Platinum Holdings Ltd
F:IPHB
|
ZA |
|
Vestas Wind Systems A/S
F:VWSA
|
DK |
|
H
|
Healthcare Realty Trust Inc
F:HR6
|
US |
|
E
|
eGain Corp
XBER:EGCA
|
US |
Innocan Pharma Corp
Innocan Pharma Corp develops drug products based on cannabinoids, the active compounds from cannabis plants, with a focus on long-acting therapies for pain relief and other medical uses. The company is trying to turn cannabis-derived ingredients into regulated pharmaceutical products rather than consumer hemp or recreational items. Its main customers are the healthcare and pharmaceutical markets, including patients, doctors, and eventually distributors or partners that can commercialize approved products. Innocan makes money through product development, licensing, and collaboration with third parties, with its value tied to moving cannabinoid science through testing, regulatory review, and into sellable medicines. What makes the business different is that it sits between the cannabis industry and drug development. Instead of selling flowers, oils, or wellness products directly to consumers, Innocan is working on injectable and topical formulations that could become prescription-grade treatments, which puts it in a more research-driven and regulated part of the market.
Innocan Pharma Corp develops drug products based on cannabinoids, the active compounds from cannabis plants, with a focus on long-acting therapies for pain relief and other medical uses. The company is trying to turn cannabis-derived ingredients into regulated pharmaceutical products rather than consumer hemp or recreational items.
Its main customers are the healthcare and pharmaceutical markets, including patients, doctors, and eventually distributors or partners that can commercialize approved products. Innocan makes money through product development, licensing, and collaboration with third parties, with its value tied to moving cannabinoid science through testing, regulatory review, and into sellable medicines.
What makes the business different is that it sits between the cannabis industry and drug development. Instead of selling flowers, oils, or wellness products directly to consumers, Innocan is working on injectable and topical formulations that could become prescription-grade treatments, which puts it in a more research-driven and regulated part of the market.
